Canakinumab in Children with Familial Mediterranean Fever: A Single-Center, Retrospective Analysis
ConclusionCanakinumab may be an effective treatment option for pediatric FMF patients with colchicine resistance, renal amyloidosis, and chronic oligoarthritis. Further studies are needed to clarify the efficacy of canakinumab in patients with a second disease, RF-positive polyarticular juvenile idiopathic arthritis.
Source: Pediatric Drugs - Category: Pediatrics Source Type: research
More News: Amyloidosis | Arthritis | Children | Colchicine | Colcrys | History of Medicine | Pediatrics | Proteinuria | Rheumatology | Study